本帖最后由 老马 于 2013-3-13 13:43 编辑 - P! \5 z' L( y9 U$ L. {: h. h
) P$ I# i* Z1 q) k+ B
健择(吉西他滨)+顺铂+阿瓦斯汀
% h( G7 h: t3 u( ^' z Gemzar +Cisplatin + Avastin Q) n, I. E/ L) b
http://annonc.oxfordjournals.org/content/21/9/1804.full1 H- h6 B8 P9 J5 d
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) 9 g# b6 w+ z- l" A- v0 t* F0 c
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
: C( i5 n, k. o+ jResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
' I( l+ f' F9 D0 F
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 196)
9 B4 L# h- g" V d
华为网盘附件:8 V2 A. l o4 B" |/ J
【华为网盘】ava.JPG
q. I+ Z% N8 ]9 f9 F; [. w/ ? |